Cardiomegaly pharmacotherapy

Cardiomegaly Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Cardiomegaly from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
MRI
CT
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiomegaly pharmacotherapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiomegaly pharmacotherapy
CDC on Cardiomegaly pharmacotherapy
Cardiomegaly pharmacotherapy in the news
Blogs on Cardiomegaly pharmacotherapy
Directions to Hospitals Treating Cardiomegaly pharmacotherapy
Risk calculators and risk factors for Cardiomegaly pharmacotherapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor in Chief: Cafer Zorkun, M.D., Ph.D. [2]

Pharmacotherapy

Acute Pharmacotherapies

• Administration of digoxin, diuretics, antiarrhythmics and/or preload and afterload reducers per clinical indication

Chronic Pharmacotherapies

A combination of diuretics and angiotensin converting enzyme (ACE) inhibition is currently the standard of care. Digoxin may reduce the frequency of rehospitalization, but does not improve mortality.

Transplantation

• In patients who are in end-stage symptomatic heart failure, a heart transplant my be necessary.